Suppr超能文献

系统性红斑狼疮患者血清白细胞介素-2水平与疾病活动度的关系及与对照组的比较

Relationship between Serum Level of Interleukin-2 in Patients with Systemic Lupus Erythematosus and Disease Activity in Comparison with Control Group.

作者信息

Sedighi Sima, Aghaei Mehrdad, Musavi Sara, Nomali Mahin

机构信息

Assistant Professor, Joint, Bone and Connective Tissue Research Centre (JBCRC), Golesatan University of Medical Sciences , Gorgan, Iran .

Medical Doctor, University of Medical Sciences , Gorgan, Iran .

出版信息

J Clin Diagn Res. 2014 Jul;8(7):MC16-8. doi: 10.7860/JCDR/2014/7903.4602. Epub 2014 Jul 20.

Abstract

BACKGROUND

Despite the large number of surveys, there are not any validated biomarkers for SLE disease activity till now. This study aimed to evaluate the relationship between serum level of IL-2 in patients with SLE and disease activity in comparison with control group.

MATERIALS AND METHODS

In this case-control study, 73 patients with lupus and 73 healthy subjects referred to the rheumatology clinic of 5 Azar Hospital in Gorgan (North of Iran).They were studied via convenience sampling during 2011-2012. Blood samples were taken from both groups and serum levels of interleukin -2 measured by Avi Bion Human IL-2 ELISA kit. Serum Level of IL-2 greater than 15 pg/ml defined positive and lesser than this amount defined negative. Disease activity evaluated with SLE disease activity index. Score greater than or equal to three or four defined as active disease. Data analysis conducted by SPSS software (version 16) and by using descriptive statistics and statistical tests.

RESULTS

Serum level of IL-2 was positive in 45.2% of sample studied and negative in 54.8% in case group, while in control group, serum level of IL-2 only in 11% of sample studied was positive and in 89% was negative. Statistical analysis indicated a significant relationship between serum level of IL-2 and the SLE disease activity index (p=0.025).

CONCLUSION

This study showed the relationship between serum levels of IL-2 and disease activity, so this biomarker can be used as a clinical indicator for assessing disease activity in patients with SLE.

摘要

背景

尽管进行了大量调查,但迄今为止尚无经过验证的系统性红斑狼疮(SLE)疾病活动生物标志物。本研究旨在评估SLE患者血清白细胞介素-2(IL-2)水平与疾病活动之间的关系,并与对照组进行比较。

材料与方法

在这项病例对照研究中,73例狼疮患者和73名健康受试者前往戈尔甘(伊朗北部)5阿扎尔医院的风湿病诊所就诊。在2011年至2012年期间通过便利抽样对他们进行研究。从两组采集血样,并使用Avi Bion人IL-2 ELISA试剂盒测量血清白细胞介素-2水平。IL-2血清水平大于15 pg/ml定义为阳性,低于此水平定义为阴性。使用SLE疾病活动指数评估疾病活动。得分大于或等于3或4定义为活动性疾病。使用SPSS软件(版本16)进行数据分析,并使用描述性统计和统计检验。

结果

病例组中45.2%的研究样本血清IL-2水平为阳性,54.8%为阴性,而在对照组中,仅11%的研究样本血清IL-2水平为阳性,89%为阴性。统计分析表明血清IL-2水平与SLE疾病活动指数之间存在显著关系(p=0.025)。

结论

本研究表明血清IL-2水平与疾病活动之间存在关联,因此该生物标志物可作为评估SLE患者疾病活动的临床指标。

相似文献

2
Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus.
Int J Rheum Dis. 2019 Aug;22(8):1419-1426. doi: 10.1111/1756-185X.13615. Epub 2019 Jun 9.
3
Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
Front Immunol. 2018 Jun 7;9:1250. doi: 10.3389/fimmu.2018.01250. eCollection 2018.
6
The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity.
Reumatismo. 2018 Dec 20;70(4):241-250. doi: 10.4081/reumatismo.2018.1075.
7
Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients.
Tohoku J Exp Med. 2018 Apr;244(4):263-270. doi: 10.1620/tjem.244.263.
9
Performance of cytokine models in predicting SLE activity.
Arthritis Res Ther. 2019 Dec 16;21(1):287. doi: 10.1186/s13075-019-2029-1.
10
Changes of Serum IL-6, IL-17, and Complements in Systemic Lupus Erythematosus Patients.
J Interferon Cytokine Res. 2019 Jul;39(7):410-415. doi: 10.1089/jir.2018.0169. Epub 2019 Jun 7.

引用本文的文献

1
RAB4A DRIVES PROINFLAMMATORY CD4 T CELL SIGNALING VIA CD38-DEPENDENT NAD METABOLISM.
Res Sq. 2025 Jun 12:rs.3.rs-6787101. doi: 10.21203/rs.3.rs-6787101/v1.
2
Th1-related transcription factors and cytokines in systemic lupus erythematosus.
Front Immunol. 2023 Dec 18;14:1305590. doi: 10.3389/fimmu.2023.1305590. eCollection 2023.
3
Genetic and molecular biology of systemic lupus erythematosus among Iranian patients: an overview.
Auto Immun Highlights. 2021 Jan 30;12(1):2. doi: 10.1186/s13317-020-00144-y.
5
Blocking of Type 1 Angiotensin II Receptor Inhibits T-lymphocyte Activation and IL-2 Production.
In Vivo. 2018 Nov-Dec;32(6):1353-1359. doi: 10.21873/invivo.11386.

本文引用的文献

1
Systemic lupus erythematosus: a review of the disease and treatment options.
Consult Pharm. 2013 Feb;28(2):110-21. doi: 10.4140/TCP.n.2013.110.
2
Biomarkers for systemic lupus erythematosus.
Int J Rheum Dis. 2012 Oct;15(5):433-44. doi: 10.1111/j.1756-185X.2012.01764.x. Epub 2012 Jul 9.
3
Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing.
J Biomed Biotechnol. 2012;2012:798924. doi: 10.1155/2012/798924. Epub 2012 May 10.
4
Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications.
Nephrol Dial Transplant. 2011 Oct;26(10):3338-44. doi: 10.1093/ndt/gfr053. Epub 2011 Mar 3.
8
Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities.
Autoimmun Rev. 2009 Sep;9(1):34-9. doi: 10.1016/j.autrev.2009.02.035. Epub 2009 Mar 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验